Efficacy of intralesional betamethasone for erosive oral lichen planus and
evaluation of recurrence: a randomized, controlled trial.
Author(s): Liu C(1), Xie B, Yang Y, Lin D, Wang C, Lin M, Ge L, Zhou H.
Affiliation(s): Author information:
(1)State Key Laboratory of Oral Diseases, Department of Oral Medicine, West China
Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.
Publication date & source: 2013, Oral Surg Oral Med Oral Pathol Oral Radiol. , 116(5):584-90
OBJECTIVE: This study aimed to determine the efficacy and safety of intralesional
betamethasone in erosive oral lichen planus and to evaluate relapse of erosion.
STUDY DESIGN: Patients were randomly assigned to the experimental group (1.4 mg
intralesional betamethasone) or to the control group (8 mg intralesional
triamcinolone acetonide), and they received injections once a week for 2 weeks.
Erosive area and pain level were assessed on days 1, 7 ± 2, and 14 ± 2. If the
lesion disappeared, any recurrence within the following 3 months was recorded.
RESULTS: Twenty-nine participants in the experimental group and 30 in the control
group completed the protocol. Healed percentage was higher with betamethasone
(93.1%) than with triamcinolone (66.7%; P = .02), and final reduction in erosion
area was greater in the experimental group (21.276 ± 21.064 mm(2)) than in the
control group (11.5 ± 12.95 mm(2); P = .02). Reduction in pain level did not
differ between groups. The proportion of participants with recurrent erosions was
significantly lower in the experimental group (14.8%) than in the control group
(45%; P = .04).
CONCLUSIONS: Intralesional betamethasone may be used in the topical treatment of
erosive oral lichen planus.
Erratum in
Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 May;117(5):655.
|